The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C-Reference-Cited by-同舟云学术

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C

Published:2023-08 Issue:2 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Shi Yaru¹,Nolan Katrina M.¹,Burton Robert L.²,Shekar Tulin¹,Murphy Rocio D.¹,Banniettis Natalie¹,Musey Luwy¹,Buchwald Ulrike K.¹

Affiliation:

1. Merck & Co., Inc., Rahway, NJ, USA

2. SunFire Biotechnologies LLC, Birmingham, AL, USA

Funder

Merck Sharp & Dohme LLC

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2235238

Reference32 articles.

1. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A

2. Comparative Immunogenicity of 7 and 13-Valent Pneumococcal Conjugate Vaccines and the Development of Functional Antibodies to Cross-Reactive Serotypes

3. The Pink Book: epidemiology and prevention of vaccine-preventable diseases. 14th ed. Chapter 17: pneumococcal disease [Internet]. Centers for Disease Control and Prevention; 2021 [accessed 2023 June 12]. https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html.

4. Pneumococcal disease [Internet]. World Health Organization; 2021 [accessed 2021 Nov 29]. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/pneumococcal-disease.

5. Current epidemiology of pneumococcal disease and pneumococcal vaccine coverage among children U.S. [Internet]. Gierke R; 2022 [accessed 2022 Sept 8]. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-02-23-24/02-pneumococcal-gierke-508.pdf.